Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy von Cortellini, A., Ricciuti, B., Facchinetti, F., Alessi, J.V.M., Venkatraman, D., Dall'Olio, F.G., Cravero, P., Vaz, V.R., Ottaviani, D., Majem, M., Piedra, A., Sullivan, I., Lee, K.A., Lamberti, G., Hussain, N., Clark, J., Bolina, A., Barba, A., Benitez, J.C., Gorría, T., Mezquita, L., Hoton, D., Aboubakar Nana, F., Besse, B., Awad, M.M., Pinato, D.J.

Volltext

1824P Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates von Dall'Olio, F.G., Lawrance, L., Zrafi, W.S., Ammari, S., Vassetsky, Y., Bône, A., Dupont, J., Busson, P., Decazes, P., Friboulet, L., Loriot, Y., Italiano, A., Lassau, N., Besse, B.

Volltext

922P Genomic instability as a biomarker for advanced cancer of the head and neck von Dall'Olio, F.G., Zrafi, W.S., Al Burshaid, D., Bassil, J., Pop, V.V., Vasseur, D., lacroix, L., Kannouche, P., Benihoud, K., Breuskin, I., Even, C.

Volltext

733P Quality of life assessment in renal cell carcinoma phase II and III clinical trials published between 2010 and 2020 von Mollica, V., Rizzo, A., Ricci, A.D., Maggio, I., Dall'Olio, F.G., Ardizzoni, A., Massari, F.

Volltext

522P Intra-arterial hepatic chemotherapy: Role beyond colorectal cancer? von El Rawadi, E.J., Boileve, A., Dall'Olio, F.G., Tarabay, A., Gelli, M., Tselikas, L., Smolenschi, C., Valery, M., Besse, B., Baudin, E., Pistilli, B., Malka, D., Hollebecque, A., Boige, V., Ducreux, M.P.

Volltext

1070P Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung c... von Dall'Olio, F.G., Lerousseau, M., Roman, G., Danlos, F-X., Aldea, M., Chaput-Gras, N., Planchard, D., Barlesi, F., Hulett, T., Marabelle, A., Besse, B.

Volltext

186P Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials von Tagliamento, M., Bruzzone, M., Ceppi, M., Genova, C., Dall'Olio, F.G., Aldea, M., Spagnolo, F., Blondeaux, E., Poggio, F., Brandão, M., Remon Masip, J., Del Mastro, L., Hendriks, L., Barlesi, F., Planchard, D., Lambertini, M., Besse, B.

Volltext

2339P Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC von F.G. dall'Olio, Vasseur, D., Mamann, A., Garcia, C.A., Beshiri, K., Marinello, A., Tagliamento, M., Ghigna, M.R., Aldea, M., Planchard, D., Pasquina, L., Barlesi, F., Italiano, A., Madison, R., Oxnard, G., Besse, B.

Volltext

2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC von Marinello, A., Ghigna, M.R., F.G. Dall'Olio, Mandarano, M., Russo, A., Raimbourg, J., Terrisse, S., Metro, G., Gazzah, A., Barlesi, F., Remon Masip, J., Planchard, D., Besse, B., Aldea, M.

Volltext

107P Baseline total metabolic tumour volume on [18F]FDG PET/CT as promising biomarker in advanced NSCLC patients treated with first line pembrolizumab von Dall'Olio, F.G., Calabrò, D., Conci, N., Argalia, G., Marchese, P., Fabbri, F., Fragomeno, B., Fanti, S., Ambrosini, V., Ardizzoni, A.

Volltext

941P PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial von Dall'Olio, F.G., Mabille, L., Garcia, C.A., Adam, J., Ghigna, M.R., Cozic, N., Caramella, C., Chaput-Gras, N., Planchard, D., Mezquita, L., Masip, J. Remon, Lavaud, P., Naltet, C., Gazzah, A., De Montpreville, V. Thomas, Mercier, O., Barlesi, F., Besse, B.

Volltext

34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions von Marinello, A., Duruisseaux, M., Zrafi, W.S., Dall'Olio, F.G., Massa, G., Iranzo, P., Tabbò, F., Guisier, F., Lindsay, C., Fallet, V., Audigier-Valette, C., Mezquita, L., Calles, A., Mountzios, G., Tagliamento, M., Raimbourg, J., Terrisse, S., Planchard, D., Besse, B., Aldea, M.

Volltext

1355P Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC von Dall'Olio, F.G., Parisi, C., Marcolin, L., Brocchi, S., Caramella, C., Conci, N., Carpani, G., Gelsomino, F., Ardizzoni, S., Marchese, P.V., Paccapelo, A., Grilli, G., Golfieri, R., Besse, B., Ardizzoni, A.

Volltext

MA03.03 CEA and CYFRA 21-1 as Prognostic Biomarkers of Benefit from Nivolumab and as a Tool in Treatment Monitoring in Advanced NSCLC von Dall'Olio, F.G., Abbati, F., Facchinetti, F., Gelsomino, F., Melotti, B., Massucci, M., Buti, S., Veneziani, M., Tiseo, M., Ardizzoni, A.

Volltext

4MO Role of ctDNA tumor fraction to select immunotherapy based regimens in advanced non-small cell lung cancer von Dall'Olio, F.G., Zrafi, W.S., Vasseur, D., Garcia, C.A., Beshiri, K., Marinello, A., Planchard, D., Lacroix, L., Barlesi, F., Rouleau, E., Italiano, A., Pasquina, L., Madison, R., Besse, B.

Volltext

1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC von Dall'Olio, F.G., C. Garcia, Bettaieb, A., Naigeon, M., Facchinetti, F., Danlos, F-X., Caramella, C., Benitez, J.C., Aldea, M., Blanc-Durand, F., Naltet, C., Abdayem, P., Lavaud, P., Ghigna, M.R., Chaput, N., Marabelle, A., Planchard, D., Barlesi, F., Soria, J-C., Besse, B.

Volltext

1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC) von Parisi, C., Benitez, J.C., Lecourt, H., Dall'Olio, F.G., Aldea, M., Blanc-Durand, F., Vergé, V., Quivoron, C., Naltet, C., Abdayem, P., Lavaud, P., Ghigna, M.R., Loriot, Y., De Botton, S., Planchard, D., Barlesi, F., Soria, J-C., Ribrag, V., Friboulet, L., Besse, B.

Volltext

Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study von Reichert, Z.R., Morgan, T.M., Li, G., Castellanos, E., Snow, T., Dall’Olio, F.G., Madison, R.W., Fine, A.D., Oxnard, G.R., Graf, R.P., Stover, D.G.

Volltext

Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM) von Grosso, F., Ceresoli, G.L., Roveta, A., Bearz, A., Valentino, F., Novello, S., Santoro, A., Cognetti, F., Amadori, D., Dall'olio, F.G., Zucchi, L., Pastorino, U., Rea, F., Boni, C., Maggioni, P., Gallizzi, G., Maconi, A., Scagliotti, G.V., Magnani, C.

Volltext

4P FDG PET derived metabolic tumor volume (MTV) and its transcriptomic correlates as biomarker to predict efficacy of immune checkpoint inhibitors (ICB) alone or in combination wit... von Dall'Olio, F.G., Garcia, C.A., Zrafi, W.S., Fortunati, E., Bettayeb, A., Zalcman, G., Remon Masip, J., Hendriks, L., Tagliamento, M., Bonardel, G., Helissey, C., Roelants, V., Fourquet, A., Aboubakar, F., Chaput-Gras, N., Passiglia, F., Monnet, I., Planchard, D., Barlesi, F., Besse, B.

Volltext